Halozyme
HALO
370 hedge funds and large institutions have $4.45B invested in Halozyme in 2023 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 135 increasing their positions, 133 reducing their positions, and 59 closing their positions.
1.44% more ownership
Funds ownership: 92.2% → 93.64% (+1.4%)
5% more call options, than puts
Call options by funds: $21M | Put options by funds: $20M
2% more repeat investments, than reductions
Existing positions increased: 135 | Existing positions reduced: 133
4% less funds holding
Funds holding: 386 → 370 (-16)
7% less capital invested
Capital invested by funds: $4.77B → $4.45B (-$314M)
24% less first-time investments, than exits
New positions opened: 45 | Existing positions closed: 59
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$48.9M |
| 2 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$34.2M |
| 3 |
Millennium Management
New York
|
+$27M |
| 4 |
State Street
Boston,
Massachusetts
|
+$18.7M |
| 5 |
Lazard Asset Management
New York
|
+$17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$81.3M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$34.6M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$28.4M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$23.4M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
-$20.8M |
HALO Hedge Fund Activity: Q2 2023 in Review
370 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Halozyme (HALO) for Q2 2023, worth a combined $4.45B — down 6.6% from $4.77B a quarter earlier.
Sellers outnumbered buyers: 59 funds closed out of HALO and 45 opened new positions — a net loss of 14 holders — while 133 trimmed existing stakes and 135 added.
The largest buyer was Marshall Wace, adding an estimated $48.9M. The largest seller was Loomis, Sayles & Company, exiting entirely with an estimated $81.3M sold.
- 370 institutional investors held Halozyme (HALO) as of Q2 2023, down from 386 in Q1 2023.
- Funds reported $4.45B of Halozyme stock for Q2 2023, down 6.6% quarter-over-quarter.
- 45 funds opened new Halozyme positions in Q2 2023 and 59 closed out, a net change of -14 holders.
- The largest Halozyme buyer in Q2 2023 was Marshall Wace, an estimated $48.9M added.
- The largest Halozyme seller in Q2 2023 was Loomis, Sayles & Company, an estimated $81.3M sold.
Based on aggregated 13F filings for Q2 2023.